N/A N=88 Randomized Single-blind Treatment

PECS II vs. MTP for Analgesia After MRM

Breast Neoplasm Female · Postoperative Pain Management

Bottom Line

View on ClinicalTrials.gov: NCT06187909 ↗

Enrolled (actual)

Serious AEs

1.2%

Results posted

Aug 2025

Primary outcome: Primary: Post-operative Pain Severity Assessed by VAS at Hour-4 — 1.4; 2.2 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: PECS II BLOCK (Procedure); MTP BLOCK (Procedure)
Age: Adult, Older Adult · 40+ yrs
Sex: Female
Sponsor: Ain Shams University
Primary completion: Jul 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Post-operative Pain Severity Assessed by VAS at Hour-4	1.4; 2.2	—
SECONDARY Post-operative Pain Severity Assessed by VAS on Admission to Postanesthesia Care Unit (PACU), at Hour-2, Hour-8, Hour-12, Hour-18 and Hour-24.	0.3; 0.3; 1.1; 1.4; 2.5; 3.2	—
SECONDARY Time of First Rescue Analgesia	12.8; 7.9	—
SECONDARY Cumulative Post-operative Nalbuphine Consumption in the First 24 Hours	8.3; 13.3	—
SECONDARY Incidence of Postoperative Side Effects and Complications	9; 12; 2; 8; 1; 3	—

Summary

This randomized controlled study aims to compare the analgesic efficacy of the ultrasound-guided modified pectoral nerve block (PECS II) and the midpoint transverse process to pleura (MTP) block in female patients undergoing modified radical mastectomy (MRM). Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS) over the first 24 hours, with additional evaluation of opioid consumption and complications.

Eligibility Criteria

Inclusion Criteria

Female patients scheduled for modified radical mastectomy (MRM).
Age between 40 and 65 years.
American Society of Anesthesiologists (ASA) physical status I-II.

Exclusion Criteria

Known allergy to local anesthetics.
Coagulopathy.
Infection at the site of injection.
Patient refusal.
Inability to understand or use the pain scale.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06187909). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.